Cell Line : OMC-1[HUMANCERVICALCARCINOMA]
Cellosaurus Index : CVCL_1623
Cellosaurus ID : OMC-1[HUMANCERVICALCARCINOMA]
GDSC1 Name
, GDSC2 Name
: OMC-1
CCLE Name
: OMC1_CERVIX
Cancer Type : urogenital_system
Dataset : All
Drug Response Information
Click to show/hide information cards below or download all drug response information.
Information cards below will change according to the dataset selected. The default dataset is “All”, which means information in the cards is based on the integration. If “All” is not selected, information cards will contain drug response information preprocessed for each dataset independently.
Experimental information
Experimental information from All dataset, including cell line name, drug name, and minimum and maximum dosages used in each experiment. Click on Dose-response to query more detail for each experiment.
| Cellosaurus ID | Drug Name | Original Dataset(s) | Min Dose | Max Dose | Dose-response |
|---|---|---|---|---|---|
| OMC-1[HUMANCERVICALCARCINOMA] | (5Z)-7-Oxozeaenol | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | 5-Fluorouracil | GDSC1,GDSC2 | 0.0200 | 32.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | 965-D2 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | 993-D2 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | A-443654 | GDSC1 | 0.0040 | 1.0240 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | A-770041 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | A-83-01 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ABT737 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ACY-1215 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Afatinib | GDSC1,GDSC2 | 0.0020 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Afuresertib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AGI-5198 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AGI-6780 | GDSC1,GDSC2 | 0.0020 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AGK-2 | GDSC2 | 0.0040 | 4.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AICA Ribonucleotide | GDSC1 | 7.8125 | 2000.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AKT inhibitor VIII | GDSC1 | 0.0100 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Alectinib | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Alisertib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Alpelisib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AMG-319 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Amuvatinib | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Apitolisib | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AR-42 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Ara-G | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ARRY-520 | GDSC1 | 0.0010 | 0.2560 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AS601245 | GDSC1 | 0.0312 | 8.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AS605240 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AST-1306 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AT-7519 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AT13148 | GDSC2 | 0.0080 | 8.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AT7867 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Avagacestat | GDSC1,GDSC2 | 0.0100 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Axitinib | GDSC1,GDSC2 | 0.0078 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZ20 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZ6102 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZ628 | GDSC1 | 0.0156 | 4.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZ960 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD1208 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD1332 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD1480 | GDSC1 | 0.0098 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD2014 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD3514 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD3759 | GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD4547 | GDSC1,GDSC2 | 0.0039 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD4877 | GDSC1 | 0.0002 | 0.0390 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD5363 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD5438 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD5582 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD6094 | GDSC1 | 0.0098 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD6482 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD6738 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD7762 | GDSC1,GDSC2 | 0.0010 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD7969 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD8055 | GDSC1 | 0.0078 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD8186 | GDSC1,GDSC2 | 0.0098 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD8835 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | AZD8931 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BAM7 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BAY ACCi | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BAY AKT1 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BAY-61-3606 | GDSC1 | 0.0312 | 8.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BAY-HDAC11_1 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BAY-HDAC11_2 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BAY-HDAC11_4 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BAY-MPS1 | GDSC1 | 0.0117 | 3.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Belinostat | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Bexarotene | GDSC1 | 0.0312 | 8.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BI-2536 | GDSC1,GDSC2 | 0.0005 | 0.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BIBF-1120 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BIBR-1532 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Bicalutamide | GDSC1,GDSC2 | 0.0040 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BIX02189 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Bleomycin | GDSC1 | 0.2500 | 64.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Bleomycin (10 uM) | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Bleomycin (50 uM) | GDSC1 | 0.1953 | 50.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BMS-345541 | GDSC1,GDSC2 | 0.0100 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BMS-509744 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BMS-536924 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BMS-754807 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Bortezomib | GDSC1,GDSC2 | 0.0000 | 0.0200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Bosutinib | GDSC1,GDSC2 | 0.0020 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BPTES | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Brivanib, BMS-540215 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Bryostatin 1 | GDSC1 | 0.0000 | 0.0080 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Buparlisib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BX-912 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | BX795 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | C-75 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Cabozantinib | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Camptothecin | GDSC2 | 0.0001 | 0.1000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CAP-232, TT-232, TLN-232 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Capivasertib | GDSC1 | 0.1172 | 30.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CAY10566 | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CAY10603 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CCT-018159 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CCT007093 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CCT245232 | GDSC1 | 0.0008 | 0.2000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CCT245467 | GDSC1 | 0.0008 | 0.2000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CD532 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Cediranib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Cetuximab | GDSC1 | 0.2570 | 65.8000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CGP-082996 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CGP-60474 | GDSC1 | 0.0010 | 0.2560 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CHIR-99021 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CI-1033 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Cisplatin | GDSC1 | 0.0117 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CMK | GDSC1 | 0.0156 | 4.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CP466722 | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CP724714 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CPI-613 | GDSC1 | 1.0000 | 256.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Crizotinib | GDSC1,GDSC2 | 0.0040 | 8.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CRT0105446 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CRT0105950 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CRT0160829 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CUDC-101 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CX-5461 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Cyclopamine | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Cyclophosphamide | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Cytarabine | GDSC1 | 0.0078 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | CZC24832 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Dabrafenib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Dacinostat | GDSC1 | 0.0040 | 1.0240 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Dactinomycin | GDSC2 | 0.0008 | 0.8000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Dactolisib | GDSC1,GDSC2 | 0.0003 | 0.2500 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Daporinad | GDSC1,GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Dasatinib | GDSC1,GDSC2 | 0.0020 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Dinaciclib | GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | DMOG | GDSC1 | 15.6250 | 4000.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Docetaxel | GDSC1,GDSC2 | 0.0000 | 0.0125 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Doramapimod | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Doxorubicin | GDSC1 | 0.0040 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Dyrk1b_0191 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | eEF2K Inhibitor, A-484954 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | EHT-1864 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Elesclomol | GDSC1,GDSC2 | 0.0002 | 0.2000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Embelin | GDSC1 | 0.1250 | 32.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Entinostat | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Entospletinib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Enzastaurin | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | EphB4_9721 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Epirubicin | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Epothilone B | GDSC1 | 0.0001 | 0.0320 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | EPZ004777 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | EPZ5676 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Erlotinib | GDSC1,GDSC2 | 0.0078 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Etoposide | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ETP-45835 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Fedratinib | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FEN1_3940 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FGFR_0939 | GDSC1 | 0.0098 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FGFR_3831 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FH535 | GDSC1 | 0.1250 | 32.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Flavopiridol | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FMK | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Foretinib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FR-180204 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FS106 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FS112 | GDSC1 | 0.0195 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FTI-277 | GDSC1 | 0.0040 | 1.0240 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FTY-720 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Fulvestrant | GDSC1,GDSC2 | 0.0010 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FY012 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FY026 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | FY069 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GDC0810 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Gefitinib | GDSC1,GDSC2 | 0.0020 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Gemcitabine | GDSC1,GDSC2 | 0.0002 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Genentech Cpd 10 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GNE-317 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GNF-2 | GDSC1 | 0.0050 | 1.2800 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK-J4 | GDSC1 | 0.1172 | 30.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK1059615 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK1070916 | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK1904529A | GDSC1,GDSC2 | 0.0040 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK2578215A | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK2606414 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK269962A | GDSC1,GDSC2 | 0.0098 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK319347A | GDSC1 | 0.0195 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK343 | GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK429286A | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK591 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK650394 | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GSK690693 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GW-2580 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GW441756 | GDSC1,GDSC2 | 0.0020 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | GW843682X | GDSC1 | 0.0010 | 0.2560 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | HG6-64-1 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | I-BET-762 | GDSC1,GDSC2 | 0.0100 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | I-BET151 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | I-BRD9 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | I-CBP112 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | IAP_5620 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | IAP_7638 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Ibrutinib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | IC-87114 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ICL1100013 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Idelalisib | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | IGFR_3801 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Imatinib | GDSC1 | 0.0078 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | IMD-0354 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | IOX2 | GDSC1,GDSC2 | 0.0004 | 0.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | IPA-3 | GDSC1 | 0.1250 | 32.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Ipatasertib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Irinotecan | GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Ispinesib Mesylate | GDSC1 | 0.0005 | 0.1280 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | IWP-2 | GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | JAK1_3715 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | JAK3_7406 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | JNJ38877605 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | JNK Inhibitor VIII | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | JNK-9L | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | JQ1 | GDSC1,GDSC2 | 0.0039 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | JQ12 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | JW-7-24-1 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | JW-7-52-1 | GDSC1 | 0.0047 | 1.2000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | kb NB 142-70 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | KIN001-042 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | KIN001-236 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | KIN001-244 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | KIN001-260 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | KIN001-266 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | KIN001-270 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Kobe2602 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | KRAS (G12C) Inhibitor-12 | GDSC2 | 0.0200 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | KU-55933 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | KU-60019 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Lapatinib | GDSC1,GDSC2 | 0.0078 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | LCL161 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | LDN-193189 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Leflunomide | GDSC2 | 0.1001 | 100.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Lenalidomide | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Lestaurtinib | GDSC1,GDSC2 | 0.0020 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | LFM-A13 | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | LGK974 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | LIMK1 inhibitor BMS4 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Linifanib | GDSC1 | 0.0040 | 1.0240 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Linsitinib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | LJI308 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Luminespib | GDSC1,GDSC2 | 0.0003 | 0.2560 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | LY2109761 | GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Masitinib | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MCT1_6447 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MCT4_1422 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MetAP2 Inhibitor, A832234 | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Methotrexate | GDSC1,GDSC2 | 0.0008 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MG-132 | GDSC1,GDSC2 | 0.0039 | 4.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Midostaurin | GDSC1 | 0.0020 | 0.5120 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MIM1 | GDSC1 | 0.1562 | 40.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MIRA-1 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Mirin | GDSC1,GDSC2 | 0.1001 | 100.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Mitomycin-C | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MK-1775 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MK-2206 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MK-8776 | GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ML323 | GDSC2 | 0.0200 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MN-64 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Motesanib | GDSC1,GDSC2 | 0.0078 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | MPS-1-IN-1 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | N22899-6-C1 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | N23918-95-7 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | N24798-49-A1 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Navitoclax | GDSC1,GDSC2 | 0.0020 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | NG-25 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Nilotinib | GDSC1,GDSC2 | 0.0078 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Niraparib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | NPK76-II-72-1 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | NSC-207895 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | NSC-87877 | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | NSC319726 | GDSC1 | 0.0010 | 0.2560 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | NU7441 | GDSC1,GDSC2 | 0.0078 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Nutlin-3a | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | NVP-ADW742 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | NVP-BHG712 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | NVP-TAE684 | GDSC1 | 0.0078 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Obatoclax Mesylate | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | OF-1 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Olaparib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Omipalisib | GDSC1 | 0.0005 | 0.1280 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | OSI-027 | GDSC1,GDSC2 | 0.0100 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | OSI-930 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Osimertinib | GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | OSU-03012 | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | OTX015 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Oxaliplatin | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | P22077 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PAC-1 | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Paclitaxel | GDSC1,GDSC2 | 0.0001 | 0.1024 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Palbociclib | GDSC1,GDSC2 | 0.0040 | 4.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Panobinostat | GDSC1 | 0.0040 | 1.0240 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PARP_0108 | GDSC1 | 0.0098 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PARP_9482 | GDSC1 | 0.0098 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PARP_9495 | GDSC1 | 0.0098 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Parthenolide | GDSC1 | 0.0195 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Pazopanib | GDSC1 | 0.0312 | 8.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PCI-34051 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PD0325901 | GDSC1,GDSC2 | 0.0010 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PD173074 | GDSC1,GDSC2 | 0.0078 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Pelitinib | GDSC1 | 0.0098 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Pemetrexed | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Pevonedistat | GDSC1,GDSC2 | 0.0039 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PF-00299804 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PF-4708671 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PF-562271 | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PFI-1 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PFI3 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PHA-665752 | GDSC1 | 0.0078 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PHA-793887 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Phenformin | GDSC1 | 15.6250 | 4000.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PI-103 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PI3Ka_4409 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Picolinici-acid | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Pictilisib | GDSC1,GDSC2 | 0.0040 | 4.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PIK-93 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Pilaralisib | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Piperlongumine | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PLK_6522 | GDSC1 | 0.0024 | 0.6250 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PLX-4720 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Ponatinib | GDSC1 | 0.0020 | 0.5120 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PRIMA-1MET | GDSC2 | 0.0300 | 30.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | PRT062607 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Pyridostatin | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Pyrimethamine | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | QL-X-138 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | QL-XI-92 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | QL-XII-47 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | QS11 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Quizartinib | GDSC1 | 0.0040 | 1.0240 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | RAF_9304 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Rapamycin | GDSC1,GDSC2 | 0.0001 | 0.1000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Refametinib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Ribociclib | GDSC2 | 0.0020 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | RO-3306 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | rTRAIL | GDSC1 | 0.0004 | 0.1000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | RU-SKI 43 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Rucaparib | GDSC1,GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Ruxolitinib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | RVX-208 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | S-Trityl-L-cysteine | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Sabutoclax | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Salubrinal | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Sapitinib | GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Saracatinib | GDSC1 | 0.0078 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Savolitinib | GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SB216763 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SB505124 | GDSC1,GDSC2 | 0.0100 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SB52334 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SB590885 | GDSC1,GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SCH772984 | GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Seliciclib | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Selisistat | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Selumetinib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Sepantronium bromide | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Serdemetan | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SGC0946 | GDSC1,GDSC2 | 0.0005 | 0.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Shikonin | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SL0101 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SN-38 | GDSC1,GDSC2 | 0.0002 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SNX-2112 | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Sorafenib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Sphingosine Kinase 1 Inhibitor II | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Staurosporine | GDSC2 | 0.0078 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | STF-62247 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | SU11274 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Sunitinib | GDSC1 | 0.0312 | 8.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | T0901317 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | TAK-715 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Talazoparib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Tamoxifen | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Tanespimycin | GDSC1,GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | TANK_1366 | GDSC1 | 0.0098 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Taselisib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Telomerase Inhibitor IX | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Temozolomide | GDSC1,GDSC2 | 0.0300 | 30.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Temsirolimus | GDSC1,GDSC2 | 0.0008 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Tenovin-6 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | TGX221 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Thapsigargin | GDSC1 | 0.0020 | 0.5120 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | THZ-2-102-1 | GDSC1 | 0.0098 | 2.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | THZ-2-49 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Tipifarnib | GDSC1 | 0.0625 | 16.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Tivozanib | GDSC1 | 0.0005 | 0.1280 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | TL-1-85 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | TL-2-105 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Torin 2 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Tozasertib | GDSC1,GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | TPCA-1 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Trametinib | GDSC1,GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Tretinoin | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Trichostatin A | GDSC1 | 0.0040 | 1.0240 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | TTK_3146 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Tubastatin A | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | TW 37 | GDSC1 | 0.0195 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | TWS119 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Ulixertinib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | UNC0638 | GDSC1 | 0.0781 | 40.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | UNC0642 | GDSC1 | 0.0020 | 0.5000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | UNC1215 | GDSC1 | 0.0039 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Uprosertib | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | VE-822 | GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | VE821 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Veliparib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Venetoclax | GDSC2 | 0.0010 | 1.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Venotoclax | GDSC1 | 0.0010 | 0.2560 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Vinblastine | GDSC1 | 0.0004 | 0.1000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Vinorelbine | GDSC1,GDSC2 | 0.0001 | 0.1000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Vismodegib | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | VNLG-124 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Vorinostat | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Voxtalisib | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | VX-11e | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | VX-702 | GDSC1 | 0.0078 | 2.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Wee1 Inhibitor | GDSC1,GDSC2 | 0.0078 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | WEHI-539 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | WH-4-023 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | WHI-P97 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | WIKI4 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Wnt-C59 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | WYE-125132 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | WZ-1-84 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | WZ3105 | GDSC1 | 0.0050 | 1.2800 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | WZ4003 | GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | XAV939 | GDSC1,GDSC2 | 0.0050 | 5.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | XMD13-2 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | XMD14-99 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | XMD15-27 | GDSC1 | 0.0400 | 10.2400 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | XMD8-85 | GDSC1 | 0.0312 | 8.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Y-39983 | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | YK-4-279 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | YM201636 | GDSC1 | 0.0200 | 5.1200 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Z-LLNle-CHO | GDSC1 | 0.0100 | 2.5600 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | Zibotentan | GDSC1 | 0.0781 | 20.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ZL049 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ZL109 | GDSC1 | 0.0391 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ZM447439 | GDSC1,GDSC2 | 0.0100 | 10.0000 |
|
| OMC-1[HUMANCERVICALCARCINOMA] | ZSTK474 | GDSC1 | 0.0200 | 5.1200 |
|
IC50
IC50 indicates how much drug dosage is needed to inhibit the cells by 50%, in vitro, compared to the control well.
Drugs with highest and lowest IC50
Drugs with highest and lowest IC50
IC90
IC90 indicates how much drug dosage is needed to inhibit the cells by 90%, in vitro, compared to the control well.
Drugs with highest and lowest IC90
Drugs with highest and lowest IC90
AUC
AUC represents the area under a dose-response curve, where 0% indicates no activity and 100% indicates that a drug completely inhibits the cells across testing dosages.
Drugs with highest and lowest AUC
Drugs with highest and lowest AUC